AKT1 and mastocytosis: There was no difference of AKT phosphorylation status in between CEACAM1‐KD and mock HMC1.2 (data not shown), therefore AKT inhibition would be necessary to treat mastocytosis completely in addition to CEACAM1‐related SHP‐1 activation.